Akums Drugs and Pharmaceuticals Limited IPO

Mainboard

Pharmaceuticals

Listed On: Aug 6, 2024 at ₹ 725.0(NSE)

₹ 14938 /22 Shares

Check Allotment

Price Summary

Last Closing

640.10 (-5.73%)

52 Week High

1,175.90

52 Week Low

530.05

Last Update

22-Nov-2024 3:30 PM

Akums Drugs and Pharmaceuticals IPO Details

30 Jul, 2024

Open Date

01 Aug, 2024

Close Date

02 Aug, 2024

Allotment Date

06 Aug, 2024

Listing Date

Issue Price

₹646-679 per equity share

Face Value

₹2 Per Equity Share

Listing at Group

BSE, NSE

Registrar

Link Intime India Private Ltd

List Price

725.0(NSE)

Listing Date

2024-08-06

Market Lot

Retail : 22 Shares (₹14,938/-)
S-HNI : 308 Shares (₹2,09,132/-)
B-HNI : 1,474 Shares (₹10,00,846/-)

Lead Manager

ICICI Securities Limited
Axis Bank Limited
Citigroup Global Markets India Private Limited
Ambit Private Limited

Issue Size

Total ₹1,856.74 Cr :
#Fresh Issue : 10,014,727 shares(aggregating up to ₹680.00 Cr) +
#OFS : 17,330,435 shares of ₹2(aggregating up to ₹1,262.83 Cr)

Retail Portion

10% (Number of Retail Applications: 1,23,292 Approx),
(Number of S-HNI Applications : 4,403 Approx),
(Number of B-HNI Applications : 8,807 Approx)

Subscription

63.44 times

IPO Docs

DRHP RHP ANCHOR

Akums Drugs and Pharmaceuticals IPO Subscription Details

As on	QIB	NII bNII sNII	Retail	Total
Shares Offered / Reserved	8,137,276	4,068,637 2,712,425 1,356,212	2,712,424	15,162,239
Day 1 - 30-07-24 05:00 PM	0.43 x	1.96 2.04 x 1.80 x	3.35 x	1.37 x
Day 2 - 31-07-24 05:00 PM	0.96 x	8.48 8.87 x 7.70 x	8.98 x	4.43 x
Day 3 - 01-08-24 05:00 PM	90.09 x	42.10 47.43 x 31.45 x	20.80 x	63.44 x

Total No. of Applications: 23,44,029 (Approx)

Retail Subscription on the basis of Applications: Retail:17.07x BHNI:9.64x SHNI:30.73x times

Akums Drugs and Pharmaceuticals Valuations

Earnings Per Share (EPS)

₹N/A/-

P/E Ratio

N/A

RoNW

N/A%

Net Asset Value (NAV) - As on 31.03.22

₹N/A

Akums Drugs and Pharmaceuticals Company Financials All values are in ₹ Cr.

	31-Mar-24	31-Mar-23	31-Mar-22
Assets	3,516.37	3,266.53	3,069.05
Revenue	4,212.21	3,700.93	3,694.52
Profit After Tax	0.79	97.82	-250.87
Net Worth	709.50	717.19	621.98
Reserves & Surplus	861.01	868.70	787.79
Total Borrowing	491.56	536.97	357.95

About The Company

Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.

The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).

As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few.

The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023).

The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF).

As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.

Akums Drugs and Pharmaceuticals - Strength and Weakness

Strength

They are the largest India-focused CDMO in terms of revenue, production capacity, and clients served during the Financial Year 2023. The pharmaceutical industry is characterised by significant barriers to entry, notably the high capital expenditure required to establish and maintain sizeable and diverse manufacturing units. Thus, big companies like Akums have an advantage.

Their R&D capabilities extend across a diverse range of dosage types, encompassing oral solids, oral liquids, injectables, sterile products, and topicals. Furthermore, their R&D efforts span various product categories, including pharmaceuticals, cosmeceuticals, nutraceuticals and ayurvedic products, among others.

Weakness

Their manufacturing units and research and development centres are concentrated in Haridwar, Uttarakhand and are thus exposed to risks originating from economic, regulatory, political and other changes in this region.

Any manufacturing or quality control concerns or their inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by their clients and distributors.

Akums Drugs and Pharmaceuticals - Peers Comparison

	P/B Ratio	P/E Ratio	RoNW	Net Worth
Akums Drugs	13.69	N/A	(0.57%)	4,212
Divi's Global	8.89	75.2	12.2%	7,845
Suven Pharma	11.3	86.8	14.1%	N/A
Gland Pharma	3.81	42.6	9.26%	5,665
Torrent Pharma	15.2	62.3	24.2%	10,728
Alkem Lab	6.05	32.7	19.5%	11,599
Eris Life	5.66	37.0	16.4%	2,009
JB Chemicals	9.87	52.2	20.4%	3,484
Mankind Pharma	8.92	50.0	19.7%	9,265
Innova Captab	4.30	37.8	17.0%	1,081

Akums Drugs and Pharmaceuticals - Promoter(s)

Pre Issue Share Holding: 84.94%

Post Issue Share Holding: N/A%

Company Promoter(s)

Sanjeev Jain
Sandeep Jain
Akums Master Trust

Akums Drugs and Pharmaceuticals IPO - Issue Objectives

Repayment/ prepayment of indebtedness of the company and its Subsidiaries
Funding incremental working capital requirements of the company
Pursuing inorganic growth initiatives through acquisitions
General corporate purposes.

Akums Drugs and Pharmaceuticals IPO - Anchor Investors

Akums Drugs and Pharmaceuticals mobilises Rs 829 crore via anchor book.

Marquee global investors Blackrock, Smallcap World Fund, Abu Dhabi Investment Authority, HSBC Global, Florida Retirement System, Carmignac Portfolio, and Neuberger Berman Emerging Markets Equity Fund bought 33.5 lakh equity shares worth Rs 227.5 crore.

SBI Mutual Fund, International Growth Fund and Income Fund, Aditya Birla Sun Life Trustee, Franklin India, Templeton India, DSP India Fund, IIFL Asset Management, Tata Mutual Fund, Motilal Oswal Mutual Fund, Bandhan Mutual Fund, Edelweiss Trusteeship, PGIM India, and JM Financial Mutual Fund also participated in the anchor book.

Insurance companies like SBI Life Insurance, ICICI Prudential Life Insurance, HDFC Life Insurance, Max Life Insurance, Aditya Birla Sun Life Insurance, Reliance Nippon Life Insurance, and Canara HSBC Life Insurance also invested in the pharma company.

Other Details

Company Contact Details

Akums Drugs and Pharmaceuticals

304, Mohan Place, LSC Saraswati Vihar, Delhi - 110 034

Phone: +91 11 6904 1000

Email: cs@akums.net

Website: http://www.akums.in/

Registrar Contact Details

Link Intime India Private Ltd

Phone: +91-22-4918 6270

Email: akumsdrugs.ipo@linkintime.co.in

Website: https://linkintime.co.in/initial_offer/public-issues.html

Akums Drugs and Pharmaceuticals IPO - FAQs

Ans. Akums Drugs and Pharmaceuticals Limited IPO is a Mainboard IPO. The issue is priced at ₹646-679 per equity share. The minimum order quantity is 22 Shares. The IPO opens on Jul 30, 2024, and closes on Aug 1, 2024. Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Ans. The Akums Drugs and Pharmaceuticals Limited IPO opens on Jul 30, 2024 and closes on Aug 1, 2024.

Ans. The size of Akums Drugs and Pharmaceuticals Limited IPO is Total ₹1,856.74 Cr : #Fresh Issue : 10,014,727 shares(aggregating up to ₹680.00 Cr) + #OFS : 17,330,435 shares of ₹2(aggregating up to ₹1,262.83 Cr).

Ans. The IPO price band is set between ₹646-679 per equity share.

Ans. To apply for Akums Drugs and Pharmaceuticals Limited IPO IPO, follow the steps given below:

- Open the IPO Ji App or Website
- Find Akums Drugs and Pharmaceuticals Limited IPO in the List of IPOs
- Press "Apply" Button
- Select Your Demat Account
- Select Your Shares Quantity and Submit
- Track Your IPO Status

Ans. The share allotment date of Akums Drugs and Pharmaceuticals Limited IPO is Aug 2, 2024.

Ans. The Akums Drugs and Pharmaceuticals Limited IPO will be listed on Aug 6, 2024.

Ans. Follow the steps to check the allotment status for Akums Drugs and Pharmaceuticals Limited IPO here.